Raghav Sundar, Senior Consultant and Principal Investigator in cancer research at National University Cancer Institute, Singapore (NCIS), shared a post on X about an article he and Samuel Klempner authored:
“Targeting Claudin18.2 beyond monoclonal antibodies like zolbetixumab is arriving! In this article by Samuel Klempner and myself in Nature Medicine we discuss two promising Claudin18.2 targeting Antibody-Drug Conjugates.”
Title: Evolution of claudin18.2 therapies in gastroesophageal cancers
Authors: Samuel J. Klempner, Raghav Sundar
Read the Full Article in Nature Medicine.
Read more posts featuring Claudin18.2 on OncoDaily.